Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Brixmor Property Group Inc.BRX · Entity 3583 | Director | June 01, 2021 | June 01, 2021 |
| ELI LILLY & CoLLY · Entity 2794 | Director | September 21, 2026 | September 22, 2026 |
| Mastercard IncMA · Entity 1763 | Director | June 16, 2026 | June 18, 2026 |
| TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063 | Director | January 01, 2018 | January 02, 2018 |
| Warby Parker Inc.WRBY · Entity 4234 | Director | June 07, 2024 | June 12, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Brixmor Property Group Inc.
Report date June 01, 2021 · Filed June 01, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 37,161 |
Reported balance
After 2021-06-01 transaction · row 1
1 source rowRow 1 · 2021-06-01 · Grant · Acquired 5,000 · Balance 37,161 F1: Represents an award of restricted stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of restricted stock.
ELI LILLY & Co
Report date September 21, 2026 · Filed September 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,012.4473 |
Reported balance
After 2026-09-21 transaction · row 1
1 source rowRow 1 · 2026-09-21 · Grant · Acquired 4.2565 · Balance 3,012.4473 F1: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. |
Filing footnotes · ownership attribution and instrument terms
F1: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service.
Mastercard Inc
Report date June 16, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 5,845 |
Reported balance
After 2026-06-16 transaction · row 1
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 509 · Balance 5,845 F1: Represents deferred stock unit award that was fully vested on June 16, 2026, the date of grant, but will settle upon termination of service by the reporting person as a director. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents deferred stock unit award that was fully vested on June 16, 2026, the date of grant, but will settle upon termination of service by the reporting person as a director.
TEVA PHARMACEUTICAL INDUSTRIES LTD
Report date January 01, 2018 · Filed January 02, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2018-01-01 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F3: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F1: Restricted share units were granted on September 3, 2015 and vest on September 3, 2018. F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2018-01-01 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F3: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4: Restricted share units were granted on May 16, 2016 and vest on May 16, 2019. F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2018-01-01 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F3: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5: Restricted share units were granted on August 11, 2017 and vest on August 11, 2020. F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted share units were granted on September 3, 2015 and vest on September 3, 2018.
F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F3: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F4: Restricted share units were granted on May 16, 2016 and vest on May 16, 2019.
F5: Restricted share units were granted on August 11, 2017 and vest on August 11, 2020.
Warby Parker Inc.
Report date June 07, 2024 · Filed June 12, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 84,024 |
Reported balance
After 2024-06-07 transaction · row 1
1 source rowRow 1 · 2024-06-07 · Grant · Acquired 14,793 · Balance 84,024 F1: Represents a grant of fully-vested restricted stock units ("RSUs"), granted pursuant to the Warby Parker Inc. Amended and Restated Non-Employee Director Compensation Program. Each RSU represents a right to receive one share of Class A Common Stock. The RSUs will be settled in shares of Class A Common Stock following the earliest to occur of: (i) the director's separation from service; (ii) a change in control of the Issuer; or (iii) the director's death. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of fully-vested restricted stock units ("RSUs"), granted pursuant to the Warby Parker Inc. Amended and Restated Non-Employee Director Compensation Program. Each RSU represents a right to receive one share of Class A Common Stock. The RSUs will be settled in shares of Class A Common Stock following the earliest to occur of: (i) the director's separation from service; (ii) a change in control of the Issuer; or (iii) the director's death.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Cerevel Therapeutics Holdings, Inc.
Report date August 01, 2024 · Filed August 05, 2024
Section 16 reporting ended · disclosed 2024-08-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2024-08-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-08-01 · Disposition to issuer · Disposed 48,415 · Balance 10,461 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest. Row 2 · 2024-08-01 · Disposition to issuer · Disposed 10,461 · Balance 0 F2: These shares are represented by restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-08-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-08-01 · Disposition to issuer · Disposed 95,242 · Balance 0 F3: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest.
F2: These shares are represented by restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration.
F3: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement.
WHOLE FOODS MARKET INC
Report date August 28, 2017 · Filed August 28, 2017
Section 16 reporting ended · disclosed 2017-08-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-08-28 transaction · row 1
1 source rowRow 1 · 2017-08-28 · Disposition to issuer · Disposed 52,501 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "merger agreement"), dated as of June 15, 2017, by and among Amazon.com, Inc., Walnut Merger Sub, Inc., and Whole Foods Market, Inc., shares of Whole Foods Market, Inc. common stock and restricted stock were converted into the right to receive $42.00 cash per share, without interest. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.25 · Expires 2018-05-13 | Direct | 0 |
Reported balance
After 2017-08-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-08-28 · Disposition to issuer · Disposed 4,500 · Balance 0 F3: Pursuant to the merger agreement, each outstanding stock option was cancelled and converted into the right to receive an amount in cash equal to the product of (a) the number of shares subject to such option multiplied by (b) the excess, if any, of the merger consideration of $42.00 over the exercise price per share of such option. F2: The option was exercisable in four equal annual installments beginning on the first anniversary of the date on which the option was granted. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.91 · Expires 2021-05-16 | Direct | 0 |
Reported balance
After 2017-08-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-08-28 · Disposition to issuer · Disposed 2,250 · Balance 0 F3: Pursuant to the merger agreement, each outstanding stock option was cancelled and converted into the right to receive an amount in cash equal to the product of (a) the number of shares subject to such option multiplied by (b) the excess, if any, of the merger consideration of $42.00 over the exercise price per share of such option. F2: The option was exercisable in four equal annual installments beginning on the first anniversary of the date on which the option was granted. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.30 · Expires 2023-05-13 | Direct | 0 |
Reported balance
After 2017-08-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-08-28 · Disposition to issuer · Disposed 2,250 · Balance 0 F3: Pursuant to the merger agreement, each outstanding stock option was cancelled and converted into the right to receive an amount in cash equal to the product of (a) the number of shares subject to such option multiplied by (b) the excess, if any, of the merger consideration of $42.00 over the exercise price per share of such option. F2: The option was exercisable in four equal annual installments beginning on the first anniversary of the date on which the option was granted. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.99 · Expires 2024-05-19 | Direct | 0 |
Reported balance
After 2017-08-28 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-08-28 · Disposition to issuer · Disposed 2,250 · Balance 0 F3: Pursuant to the merger agreement, each outstanding stock option was cancelled and converted into the right to receive an amount in cash equal to the product of (a) the number of shares subject to such option multiplied by (b) the excess, if any, of the merger consideration of $42.00 over the exercise price per share of such option. F2: The option was exercisable in four equal annual installments beginning on the first anniversary of the date on which the option was granted. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "merger agreement"), dated as of June 15, 2017, by and among Amazon.com, Inc., Walnut Merger Sub, Inc., and Whole Foods Market, Inc., shares of Whole Foods Market, Inc. common stock and restricted stock were converted into the right to receive $42.00 cash per share, without interest.
F2: The option was exercisable in four equal annual installments beginning on the first anniversary of the date on which the option was granted.
F3: Pursuant to the merger agreement, each outstanding stock option was cancelled and converted into the right to receive an amount in cash equal to the product of (a) the number of shares subject to such option multiplied by (b) the excess, if any, of the merger consideration of $42.00 over the exercise price per share of such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 21, 2026 Filed Sep 22, 2026 20:15 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 4.2565 | $1,164.89 | $4,958.35 |
DisclosureSEC source: 0001262388-26-000018 · wk-form4_1790108122.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,012.4473 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| August 17, 2026 Filed Aug 18, 2026 20:24 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 4.1908 | $1,183.16 | $4,958.39 |
DisclosureSEC source: 0001262388-26-000016 · wk-form4_1787084689.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,003.9096 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| July 20, 2026 Filed Jul 21, 2026 20:40 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 4.3232 | $1,146.90 | $4,958.28 |
DisclosureSEC source: 0001262388-26-000014 · wk-form4_1784666431.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,999.7188 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| June 16, 2026 Filed Jun 18, 2026 20:04 UTC | Mastercard Inc MA · Entity 1763 | GrantClass A Common Stock | 509 | $0.00 | $0.00 |
DisclosureSEC source: 0001141391-26-000055 · wk-form4_1781813080.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,845 F1 · shares: Represents deferred stock unit award that was fully vested on June 16, 2026, the date of grant, but will settle upon termination of service by the reporting person as a director. Read SEC document |
| June 15, 2026 Filed Jun 16, 2026 20:25 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 4.3904 | $1,129.35 | $4,958.30 |
DisclosureSEC source: 0001262388-26-000012 · wk-form4_1781641539.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,995.3956 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| May 18, 2026 Filed May 19, 2026 20:19 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 5.018 | $988.09 | $4,958.24 |
DisclosureSEC source: 0001262388-26-000010 · wk-form4_1779221994.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,986.617 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 20:20 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 5.39 | $919.90 | $4,958.26 |
DisclosureSEC source: 0001262388-26-000008 · wk-form4_1776802850.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,981.599 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 20:32 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 5.013 | $989.12 | $4,958.46 |
DisclosureSEC source: 0001262388-26-000006 · wk-form4_1773779547.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,976.209 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| February 17, 2026 Filed Feb 18, 2026 21:27 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 4.786 | $1,036.05 | $4,958.54 |
DisclosureSEC source: 0001262388-26-000004 · wk-form4_1771450040.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,966.222 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| January 20, 2026 Filed Jan 21, 2026 21:27 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 4.762 | $1,041.29 | $4,958.62 |
DisclosureSEC source: 0001262388-26-000002 · wk-form4_1769030817.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,961.436 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| December 15, 2025 Filed Dec 16, 2025 21:46 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 4.668 | $1,062.19 | $4,958.30 |
DisclosureSEC source: 0001262388-25-000010 · wk-form4_1765921596.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,956.674 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| November 17, 2025 Filed Nov 18, 2025 21:26 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 215.327 | $1,021.70 | $219,999.60 |
DisclosureSEC source: 0001262388-25-000008 · wk-form4_1763501198.xml · nonDerivative · entry 2 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,948.32 Read SEC document |
| November 17, 2025 Filed Nov 18, 2025 21:26 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 4.853 | $1,021.70 | $4,958.31 |
DisclosureSEC source: 0001262388-25-000008 · wk-form4_1763501198.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,732.993 F1 · shares: At the election of the reporting person, the shares reported as acquired in this row have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| October 20, 2025 Filed Oct 22, 2025 20:24 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 6.129 | $808.96 | $4,958.12 |
DisclosureSEC source: 0001262388-25-000006 · wk-form4_1761164695.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,728.14 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| September 15, 2025 Filed Sep 17, 2025 20:49 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 6.627 | $748.19 | $4,958.26 |
DisclosureSEC source: 0001262388-25-000004 · wk-form4_1758142191.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,721.97 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| August 18, 2025 Filed Aug 19, 2025 20:23 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 7.103 | $698.05 | $4,958.25 |
DisclosureSEC source: 0000059478-25-000232 · wk-form4_1755634987.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,710.158 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| August 12, 2025 Filed Aug 12, 2025 20:19 UTC | ELI LILLY & Co LLY · Entity 2794 | PurchaseCommon Stock | 117 | $641.18 | $75,018.29 |
DisclosureSEC source: 0000059478-25-000212 · wk-form4_1755029946.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,703.055 Read SEC document |
| July 21, 2025 Filed Jul 22, 2025 20:55 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 6.505 | $762.18 | $4,957.98 |
DisclosureSEC source: 0000059478-25-000194 · wk-form4_1753217727.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,586.055 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| June 24, 2025 Filed Jun 26, 2025 20:33 UTC | Mastercard Inc MA · Entity 1763 | GrantClass A Common Stock | 458 | $0.00 | $0.00 |
DisclosureSEC source: 0001141391-25-000150 · wk-form4_1750969990.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,336 F1 · shares: Represents deferred stock unit award that was fully vested on June 24, 2025, the date of grant, but will settle upon termination of service by the reporting person as a director. Read SEC document |
| June 16, 2025 Filed Jun 17, 2025 22:28 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 6.14 | $807.58 | $4,958.54 |
DisclosureSEC source: 0000059478-25-000176 · wk-form4_1750199300.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,579.55 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| May 19, 2025 Filed May 20, 2025 20:25 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 6.566 | $755.11 | $4,958.05 |
DisclosureSEC source: 0000059478-25-000154 · wk-form4_1747772733.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,568.651 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| April 21, 2025 Filed Apr 22, 2025 20:22 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 6.061 | $818.02 | $4,958.02 |
DisclosureSEC source: 0000059478-25-000124 · wk-form4_1745353361.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,562.085 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 20:27 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 6.012 | $824.76 | $4,958.46 |
DisclosureSEC source: 0000059478-25-000103 · wk-form4_1742416067.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,556.024 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| February 18, 2025 Filed Feb 19, 2025 21:23 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 5.784 | $857.20 | $4,958.04 |
DisclosureSEC source: 0000059478-25-000077 · wk-form4_1740000210.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,545.394 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| January 21, 2025 Filed Jan 23, 2025 21:24 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 6.679 | $742.35 | $4,958.16 |
DisclosureSEC source: 0000059478-25-000016 · wk-form4_1737667469.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,539.61 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| December 16, 2024 Filed Dec 17, 2024 21:23 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 12.73 | $779.00 | $9,916.67 |
DisclosureSEC source: 0000059478-24-000291 · wk-form4_1734470584.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,532.931 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 21:28 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 302.53 | $727.20 | $219,999.82 |
DisclosureSEC source: 0000059478-24-000276 · wk-form4_1732138122.xml · nonDerivative · entry 2 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,516.624 Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 21:28 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 13.637 | $727.20 | $9,916.83 |
DisclosureSEC source: 0000059478-24-000276 · wk-form4_1732138122.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,214.094 F1 · shares: At the election of the reporting person, the shares acquired in this row have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| October 21, 2024 Filed Oct 22, 2024 20:23 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 11 | $906.13 | $9,967.43 |
DisclosureSEC source: 0000059478-24-000238 · wk-form4_1729628600.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,201 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 21:19 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 11 | $923.54 | $10,158.94 |
DisclosureSEC source: 0000059478-24-000225 · wk-form4_1726607955.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,190 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 20:18 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 11 | $921.81 | $10,139.91 |
DisclosureSEC source: 0000059478-24-000206 · wk-form4_1724185087.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,176 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 16:32 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Disposition to issuerStock Option (Right to Buy) · Derivative | 95,242 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-090833 · ownership.xml · derivative · entry 3 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 95,242 shares Expires not disclosed F3 · derivative.exercise_price: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. F3 · price: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. F3 · derivative.exercise_date: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. F3 · derivative.expiration_date: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 16:32 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Disposition to issuerCommon Stock | 10,461 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-090833 · ownership.xml · nonDerivative · entry 2 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · shares: These shares are represented by restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration. F2 · price: These shares are represented by restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 16:32 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Disposition to issuerCommon Stock | 48,415 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-090833 · ownership.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,461 F1 · shares: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest. F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest. Read SEC document |
| July 15, 2024 Filed Jul 16, 2024 20:22 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 10 | $950.46 | $9,504.60 |
DisclosureSEC source: 0000059478-24-000174 · wk-form4_1721161365.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,165 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| June 18, 2024 Filed Jun 21, 2024 19:50 UTC | Mastercard Inc MA · Entity 1763 | GrantClass A Common Stock | 545 | $0.00 | $0.00 |
DisclosureSEC source: 0001141391-24-000149 · wk-form4_1718999417.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,878 F1 · shares: Represents deferred stock unit award that was fully vested on June 18, 2024, the date of grant, but will be settled upon termination of service by the reporting person as a director. Read SEC document |
| June 17, 2024 Filed Jun 18, 2024 20:23 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 11 | $885.01 | $9,735.11 |
DisclosureSEC source: 0000059478-24-000156 · wk-form4_1718742175.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,155 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| June 07, 2024 Filed Jun 12, 2024 01:30 UTC | Warby Parker Inc. WRBY · Entity 4234 | GrantClass A Common Stock | 14,793 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-070568 · tm2417040-7_4seq1.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,024 F1 · shares: Represents a grant of fully-vested restricted stock units ("RSUs"), granted pursuant to the Warby Parker Inc. Amended and Restated Non-Employee Director Compensation Program. Each RSU represents a right to receive one share of Class A Common Stock. The RSUs will be settled in shares of Class A Common Stock following the earliest to occur of: (i) the director's separation from service; (ii) a change in control of the Issuer; or (iii) the director's death. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 16:28 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | GrantCommon Stock | 10,461 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-070694 · ownership.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,876 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. 100% of the RSUs subject to this grant shall vest upon the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the 2025 annual meeting of stockholders of the Company. F1 · price: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. 100% of the RSUs subject to this grant shall vest upon the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the 2025 annual meeting of stockholders of the Company. Read SEC document |
| May 20, 2024 Filed May 21, 2024 20:24 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 13 | $783.18 | $10,181.34 |
DisclosureSEC source: 0000059478-24-000137 · wk-form4_1716323062.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,141 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| April 15, 2024 Filed Apr 16, 2024 20:14 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 13 | $750.77 | $9,760.01 |
DisclosureSEC source: 0000059478-24-000111 · wk-form4_1713298480.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,128 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| March 18, 2024 Filed Mar 19, 2024 20:23 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 13 | $762.66 | $9,914.58 |
DisclosureSEC source: 0000059478-24-000092 · wk-form4_1710879793.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,115 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| February 20, 2024 Filed Feb 21, 2024 21:26 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 13 | $755.66 | $9,823.58 |
DisclosureSEC source: 0000059478-24-000075 · wk-form4_1708550776.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,098 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| January 16, 2024 Filed Jan 17, 2024 21:19 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 16 | $634.57 | $10,153.12 |
DisclosureSEC source: 0000059478-24-000010 · wk-form4_1705526334.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,085 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| December 18, 2023 Filed Dec 19, 2023 21:16 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 9 | $579.76 | $5,217.84 |
DisclosureSEC source: 0000059478-23-000328 · wk-form4_1703020592.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,069 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| November 20, 2023 Filed Nov 21, 2023 21:30 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 335 | $597.60 | $200,196.00 |
DisclosureSEC source: 0000059478-23-000312 · wk-form4_1700602226.xml · nonDerivative · entry 2 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,057 Read SEC document |
| November 20, 2023 Filed Nov 21, 2023 21:30 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 8 | $597.60 | $4,780.80 |
DisclosureSEC source: 0000059478-23-000312 · wk-form4_1700602226.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,722 F1 · shares: At the election of the reporting person, the shares acquired in this row have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| October 16, 2023 Filed Oct 17, 2023 20:24 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 8 | $616.64 | $4,933.12 |
DisclosureSEC source: 0000059478-23-000276 · wk-form4_1697574262.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,714 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| September 18, 2023 Filed Sep 20, 2023 20:29 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 9 | $571.28 | $5,141.52 |
DisclosureSEC source: 0000059478-23-000261 · wk-form4_1695241761.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,706 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| August 29, 2023 Filed Feb 13, 2024 16:16 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | GiftCommon Stock | 562 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-014586 · ownership.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,415 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.